Displaying drugs 626 - 650 of 9432 in total
Givosiran
Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic...
Approved
Investigational
Carglumic acid
Carglumic acid is a drug used for the treatment of hyperammonemia in patients with a deficiency in N-acetyl glutamate synthase. This rare genetic disorder results in elevated blood levels of ammonia, which can eventually cross the blood–brain barrier and cause neurologic problems, cerebral edema, coma, and death. Carglumic acid was...
Approved
Amylmetacresol
Amylmetacresol is an antiseptic available in Canada over-the-counter in a number of lozenges for the treatment of sore throat and minor mouth infections , . Amylmetacresol is often combined with dichlorobenzyl alcohol and menthol in the commonly used sore throat lozenges, known as Strepsils .
The acute sore throat (pharyngitis)...
Approved
Chromium nicotinate
Approved
Experimental
Belzutifan
Belzutifan is an inhibitor of hypoxia-inducible factor 2α (HIF-2α) used in the treatment of von Hippel-Lindau (VHL) disease-associated cancers. The HIF-2α protein was first identified in the 1990s by researchers at UT Southwestern Medical Center as a key player in the growth of certain cancers. Initially considered to be undruggable,...
Approved
Investigational
Matched Iupac: … 3-{[(1S,2S,3R)-2,3-difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1H-inden-4-yl]oxy}-5-fluorobenzonitrile …
Omega-3-carboxylic acids
The omega-3 carboxylic acid (OM3-CA) is a new formulation of omega-3 fatty acids that present an enhanced bioavailability in the treatment of dyslipidemia. The increased bioavailability is explained because OM3-CA is found in a form of polyunsaturated free fatty acids as opposed to other products whose form is as ethyl...
Approved
Investigational
Remestemcel-L
Remestemcel-L is a third-party, off-the-shelf suspension of ex-vivo cultured adult human mesenchymal stem cells intended for intravenous infusion. The mesenchymal stem cells are derived from the bone marrow of unrelated and human leukocyte antigen (HLA)–unmatched healthy adult donors and have the ability to differentiate into different tissue cells. It was...
Approved
Investigational
Butorphanol
A synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain.
Approved
Illicit
Vet approved
Matched Categories: … Heterocyclic Compounds with 4 or More Rings …
Terconazole
Terconazole is an anti-fungal drug that is mainly used to treat vaginal yeast infections (or vaginal candidiasis). It is classified as a triazole ketal derivative. Terconazole was initially approved by the FDA in 1987.[FDA label] This drug is available in cream and suppository forms and both have demonstrated high levels...
Approved
Matched Iupac: … )-4-(propan-2-yl)piperazine ... 1-(4-{[(2S,4R)-2-(2,4-dichlorophenyl)-2-[(1H-1,2,4-triazol-1-yl)methyl]-1,3-dioxolan-4-yl]methoxy}phenyl …
Matched Description: … [A178093]Due to the existence of 2 stereocentres, there are 4 possible stereoisomers for terconazole. …
Matched Description: … [A178093]Due to the existence of 2 stereocentres, there are 4 possible stereoisomers for terconazole. …
Penbutolol
Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high binding affinity to the...
Approved
Investigational
Ixekizumab
Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A has...
Approved
Investigational
Matched Description: … Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin …
Flurandrenolide
A corticosteroid used topically in the treatment of various skin disorders. It is usually employed as a cream or an ointment, and is also used as a polyethylene tape with an adhesive. (From Martindale, The Extra Pharmacopoeia, 30th ed, p733)
Approved
Plantago lanceolata pollen
Plantago lanceolata pollen is the pollen of the Plantago lanceolata plant. Plantago lanceolata pollen is mainly used in allergenic testing.
Approved
Matched Mixtures name: … 4 Weed Mix ... 4 Weed Mix ... 4 Weed Mix …
Sodium tartrate
Sodium tartrate is a disodium salt of l-( + )-tartaric acid that is identified by transparent, colorless, and odorless crystals. It is obtained as a byproduct of wine manufacturing. Sodium tartrate is generally recognized as safe (GRAS) as a direct human food ingredient. It acts as an emulsifier and pH...
Approved
Matched Description: … This compound is commonly used as an emulsifier in cheese/cheese spread products and is not to exceed 4% …
Patent Blue
Patent blue is aniline dye and it is one of the most common dyes used. It is a sodium or calcium salt of diethylammonium hydroxide inner salt. It has the chemical designation of (4-(alpha-(p-(diethylamino)phenyl)-2,4-disulfobenzylidene)-2,5-cyclohexadiene-1-ylidene)diethylammonium hydroxide. Patent blue was developed by Guerbet and approved by Health Canada on December 31, 1979....
Approved
Matched Iupac: … 4-{[4-(diethylamino)phenyl](5-hydroxy-2,4-disulfophenyl)methylidene}-N,N-diethylcyclohexa-2,5-dien-1- …
Matched Description: … [A32574] It has the chemical designation of (4-(alpha-(p-(diethylamino)phenyl)-2,4-disulfobenzylidene …
Matched Salts cas: … 20262-76-4 …
Matched Description: … [A32574] It has the chemical designation of (4-(alpha-(p-(diethylamino)phenyl)-2,4-disulfobenzylidene …
Matched Salts cas: … 20262-76-4 …
Eflornithine
Eflornithine is an irreversible ornithine decarboxylase inhibitor originally developed as a treatment for human African trypanosomiasis. Further research has also implicated ornithine decarboxylase in other conditions like facial hirsutism and cancer, especially when ornithine decarboxylase is highly upregulated in tumor cells.[A4112, A262834] Additionally, ornithine decarboxylase is activated by c-myc or...
Approved
Withdrawn
Dacomitinib
Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was developed by Pfizer Inc and approved by the FDA on...
Approved
Investigational
Matched Iupac: … (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}-4-(piperidin-1-yl)but-2-enamide …
Matched Description: … Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone …
Matched Description: … Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone …
Salmeterol
Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, salbutamol. Salmeterol was first described in the literature in 1988. Salmeterol's structure...
Approved
Matched Iupac: … 4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)-2-(hydroxymethyl)phenol …
Matched Description: … [A183737] Salmeterol was granted FDA approval on 4 February 1994.[L11542] …
Matched Description: … [A183737] Salmeterol was granted FDA approval on 4 February 1994.[L11542] …
Crizanlizumab
Crizanlizumab is a humanized IgG2 monoclonal antibody used to reduce the frequency of vaso-occlusive crises in patients with sickle cell disease. Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Africa, and certain parts of India. The genetic mutation associated with this disease leads to the...
Approved
Investigational
Matched Description: … [A187907] Crizanlizumab, or SEG101, is given once every 4 weeks and may improve patient adherence. …
Tinzaparin
Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for high affinity binding...
Approved
Cianidanol
An antioxidant flavonoid, occurring especially in woody plants as both (+)-catechin and (-)-epicatechin (cis) forms.
Approved
Withdrawn
Matched Salts cas: … 88191-48-4 …
D-Methionine
Approved
Experimental
Investigational
Matched Iupac: … (2R)-2-amino-4-(methylsulfanyl)butanoic acid …
Matched Mixtures name: … NUTRINEAL PD]4 Peritoneal Dialysis Solution with 1.1% Amino Acids …
Matched Mixtures name: … NUTRINEAL PD]4 Peritoneal Dialysis Solution with 1.1% Amino Acids …
Ibandronate
Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to zoledronic acid, minodronic acid, and risedronic acid.[A203111,A203138] It is used to prevent and treat postmenopausal osteoporosis.[L13805,L13808] Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs. Ibandronate was granted FDA...
Approved
Investigational
Matched Products: … BONVİVA 3 MG/3 ML ENJEKSİYONLUK ÇÖZELTİ, 4 ADET …
Displaying drugs 626 - 650 of 9432 in total